Introduction
Materials and methods
Study group
Factor | Study group (n = 62) |
---|---|
Gender | |
Male | 51 (82.2%) |
Female | 11 (17.8%) |
Age, median (range) | 63 (42–87) |
≥ 63 | 32 (48.4% |
< 63 | 30 (51.6%) |
Histopathological diagnosis | |
Squamous-cell carcinoma | 57 (91.9%) |
Other | 5 (8.1%) |
Tumor location | |
Upper throat | 17 (27.4%) |
Lower throat | 45 (72.6%) |
Larynx | 34 (54.8%) |
Others | 28 (45.2%) |
T stage | |
T1 | 2 (3.2%) |
T2 | 9 (14.5%) |
T3 | 15 (24.2%) |
T4 | 36 (58.1%) |
N stage | |
Nx | 2 (3.2%) |
N0 | 18 (29%) |
N1 | 6 (9.7%) |
N2 | 32(51.6%) |
N3 | 4 (6.5%) |
M stage | |
Mx | 3(75%) |
M1 | 1 (25%) |
Disease stage | |
I | 2 (3.2%) |
III | 12 (19.4%) |
IVA | 40 (64.5%) |
IVB | 3 (4.8%) |
IVC | 5 (8.1%) |
Performance status (PS) | |
≤ 1 | 55 (88.7%) |
> 1 | 7 (11.3%) |
Type of treatment | |
Surgery + RTH | 28 (45.2%) |
Surgery + chemoradiation | 17 (27.4%) |
RTH alone | 7 (11.3%) |
Induction CHTH + RTH | 3 (4.8%) |
Concurrent chemoradiation | 7 (11.3%) |
Alcohol consumption | |
Yes | 28 (45.2%) |
No | 34 (54.8%) |
Smoking status | |
Smoker | 52 (83.9%) |
Non-smoker | 10 (16.1%) |
Current smoker | 45 (86.5%) |
Former smoker | 7 (13.5%) |
Nutritional status | |
Parenteral nutrition | |
Yes | 13 (21%) |
No | 49 (79%) |
Weight (kg) | |
Mean ± SD | 65.63 ± 11.93 |
BMI | |
Mean ± SD | 23.13 ± 4.44 |
> 18.5 | 52 (83.9%) |
< 18.5 | 10 (16.1%) |
SGA | |
A | 9 (14.5%) |
B | 29 (46.8%) |
C | 24 (38.7%) |
NRS | |
2 | 42 (67.8%) |
3 | 18 (29%) |
4 | 2 (3.2) |
Total protein (g/L) | |
Median ± SD | 6.72 ± 0.52 |
Albumin (g/L) | |
Median ± SD | 3.33 ± 0.24 |
Prealbumin(g/dL) | |
Median ± SD | 0.20 ± 0.08 |
Transferrin(g/L) | |
Median ± SD | 2.50 ± 0.60 |
Genotyping and ELISA
Statistical analysis
Results
Factor | A | B and C | p OR [95% CI] | A and B | C | p OR [95% CI] |
---|---|---|---|---|---|---|
SGA | ||||||
Gender | ||||||
Male | 7 (13.7%) | 44 (86.3%) | 0.705 0.716 [0.127–4.03] | 32 (62.6%) | 19 (37.4%) | 0.614 1.404 [0.377–5.231] |
Female | 2 (18.2%) | 9 (81.8%) | 6 (54.5%) | 5 (45.5%) | ||
Age (years) | ||||||
≥ 63 | 7 (21.9%) | 25 (78.1%) | 0.107 3.92 [0.744–20.65] | 20 (62.5%) | 12 (37.5%) | 0.840 1.111 [0.40–3.09] |
< 63 | 2 (6.7%) | 28 (93.3%) | 18 (60%) | 12 (40%) | ||
Performance status (PS) | ||||||
< 1 | 9 (16.4%) | 46 (83.6%) | 0.456 3.065 [0.161–58.35] | 36 (65.5%) | 19 (34.5%) | 0.08 4.737 [0.839–26.76] |
> 1 | 0 | 7 | 2 (28.6%) | 5 (71.4%) | ||
Histopathological diagnosis | ||||||
Squamous-cell carcinoma | 8 (14%) | 49 (86%) | 0.718 0.653 [0.064–6.614] | 33 (57.9%) | 24 (42.1%) | 0.165 0.124 [0.007–2.355] |
Others | 1 (20%) | 4 (80%) | 5 | 0 | ||
Disease stage | ||||||
I and III | 2 (14.3%) | 12 (85.7%) | 0.978 0.976 [0.179–5.333] | 10 (71.4%) | 4 (28.6%) | 0.380 1.786 [0.490–6.512] |
IV | 7 (14.6%) | 41 (85.4%) | 28 (58.3%) | 20 (41.7%) | ||
Tumor location | ||||||
Upper throat | 3 (17.6%) | 14 (82.4%) | 0.668 1.393 [0.306–6.333] | 13 (76.5%) | 4 (23.5%) | 0.139 2.600 [0.733–9.217] |
Lower throat | 6 (13.3%) | 39 (86.7%) | 25 (55.6%) | 20 (44.4%) | ||
Larynx | 5 (14.7%) | 29 (85.3%) | 0.963 1.035 [0.250–4.287] | 19 (55.9%) | 15 (44.1%) | 0.337 0.600 [0.212–1.702] |
Others | 4 (14.3%) | 24 (85.7%) | 19 (67.9%) | 9 (32.1%) | ||
Alcohol consumption | ||||||
Yes | 4 (14.3%) | 24 (85.7%) | 0.963 0.967 [0.233–4.001] | 14 (50%) | 14 (50%) | 0.101 0.417 [0.147–1.185] |
No | 5 (14.7%) | 29 (85.3%) | 24 (70.6%) | 10 (29.4%) | ||
Smoking status | ||||||
Smoker | 8 (15.4%) | 44 (84.6%) | 0.661 1.636 [0.182–14.75] | 31 (59.6%) | 21 (40.4%) | 0.539 0.633 [0.147–2.729] |
Non-smoker | 1 (10%) | 9 (90%) | 7 (70%) | 3 (30%) | ||
Concurrent CTH | ||||||
Yes | 2 (8.3%) | 22 (91.7%) | 0.284 0.403 [0.076–2.125] | 13 (54.3%) | 11 (45.7%) | 0.362 0.615 [0.216–1.749] |
No | 7 (18.4%) | 31 (81.6%) | 25 (65.8%) | 13 (34.2%) | ||
BMI (I) All patients | ||||||
< 24.9 | 4 (10%) | 37 (90%) | 0.148 0.346 [0.082–1.460] | 21 (51.2%) | 20 (48.8%) | 0.028 4.048 [2.160–14.12] |
> 25 | 5 (23.8%) | 16 (76.2%) | 17 (70.8%) | 4 (29.2%) | ||
< 18.5 | 1 (10%) | 9 (90%) | 0.661 0.611 [0.068–5.510] | 4 (40%) | 6 (60%) | 0.141 0.353 [0.088–1.414] |
> 18.5 | 8 (15.4%) | 44 (84.6%) | 34 (65.4%) | 18 (34.6%) | ||
Weight loss (I vs VII) All patients | ||||||
< 5% | 2 (6.7%) | 28 (93.3%) | 0.107 0.255 [0.048–1.344] | 23 (76.7%) | 7 (23.3%) | 0.019 3.724 [1.246–11.13] |
> 5% | 7 (21.9%) | 25 (78.1%) | 15 (46.9%) | 17 (53.1%) | ||
< 10% | 4 (10%) | 36 (90%) | 0.137 0.333 [0.078–1.416] | 22 (55%) | 18 (45%) | 0.175 0.458 [0.149–1.414] |
> 10% | 5 (25%) | 15 (75%) | 16 (72.7%) | 6 (27.3%) | ||
Genotype distribution of TNF-α −1031T/C | ||||||
CC | 0 | 6 | 0.527 0.385 [0.020–7.420] | 1 (11.1%) | 5 (88.9%) | 0.044 9.737 [1.061–89.40] |
CT and TT | 9 (16.1%) | 47 (83.9%) | 37 (66.1%) | 19 (33.9%) | ||
TT | 9 (24.3%) | 28 (75.7%) | 0.055 17.0 [0.941–306.99] | 31 (83.8%) | 6 (16.2%) | 0.0001 13.29 [3.862–45.70] |
CT and CC | 0 | 25 | 7 (28%) | 18 (72%) |
Factor (median ± SD) | CC | CT | TT |
p
| CT and CC | TT |
p
|
---|---|---|---|---|---|---|---|
TNF-α −1031T/C | |||||||
Weight (kg) (I) all patients | 55 ± 11.64 | 60 ± 7.07 | 64 ± 9.01 | 0.042 | 58 ± 7.83 | 64 ± 9.01 | 0.044 |
Weight (kg) (I) men | 61 ± 8.21 | 63 ± 7.43 | 69 ± 10.99 | 0.049 | 61 ± 7.06 | 69 ± 10.99 | 0.012 |
Weight (kg) (I) women | 53 ± 8.72 | 55 ± 9.52 | 62.5 ± 9.65 | 0.133 | 53.5 ± 8.24 | 62.5 ± 9.65 | 0.045 |
Weight (kg) (VII) all patients | 51 ± 10.23 | 58 ± 8.67 | 60 ± 9.76 | 0.389 | 58 ± 9.02 | 60 ± 9.76 | 0.322 |
Weight (kg) (VII) men | 60 ± 4.35 | 58 ± 8.85 | 60 ± 9.73 | 0.381 | 58.5 ± 8.22 | 60 ± 9.73 | 0.350 |
Weight (kg) (VII) women | 51 ± 5.77 | 66 ± 8.49 | 55 ± 10.03 | 0.090 | 51 ± 11.64 | 55 ± 10.03 | 0.840 |
BMI (I) all patients | 19.95 ± 4.49 | 22.83 ± 4.59 | 23.54 ± 4.07 | 0.122 | 22.71 ± 4.74 | 23.54 ± 4.07 | 0.179 |
BMI (I) men | 23.09 ± 2.08 | 22.58 ± 4.19 | 24.09 ± 4.40 | 0.464 | 22.84 ± 3.97 | 24.09 ± 4.40 | 0.429 |
BMI (I) women | 17.96 ± 3.73 | 20.85 ± 3.23 | 21.43 ± 3.73 | 0.186 | 19.95 ± 7.45 | 21.43 ± 3.73 | 0.093 |
BMI (VII) all patients | 20.22 ± 4.95 | 19.53 ± 4.18 | 19.37 ± 3.67 | 0.866 | 19.53 ± 4.29 | 19.37 ± 3.67 | 0.908 |
BMI (VII) men | 22.53 ± 3.05 | 19.53 ± 3.58 | 21.05 ± 3.81 | 0.343 | 20.07 ± 3.63 | 21.05 ± 3.81 | 0.860 |
BMI (VII) women | 16.65 ± 2.91 | 18.81 ± 0.76 | 19.00 ± 3.76 | 0.348 | 18.52 ± 2.46 | 19.00 ± 3.76 | 0.315 |
Transferrin (g/L) | 2.80 ± 0.47 | 2.50 ± 0.61 | 2.50 ± 0.60 | 0.279 | 2.60 ± 0.59 | 2.50 ± 0.60 | 0.421 |
Prealbumin (g/dL) | 0.3 ± 0.05 | 0.2 ± 0.08 | 0.2 ± 0.08 | 0.355 | 0.25 ± 0.08 | 0.2 ± 0.08 | 0.178 |
TP (g/L) (I) | 6.64 ± 0.53 | 6.73 ± 0.48 | 6.71 ± 0.55 | 0.985 | 6.73 ± 0.48 | 6.71 ± 0.55 | 0.943 |
TP (g/L) (VII) | 5.83 ± 0.66 | 6.36 ± 0.59 | 6.46 ± 0.60 | 0.036 | 6.26 ± 0.56 | 6.46 ± 0.60 | 0.048 |
Albumin (g/L) (I) | 3.19 ± 0.13 | 3.26 ± 0.20 | 3.38 ± 0.24 | 0.048 | 3.23 ± 0.19 | 3.38 ± 0.24 | 0.047 |
Albumin (g/L) (VII) | 2.98 ± 0.62 | 3.11 ± 0.44 | 3.28 ± 0.38 | 0.031 | 3.04 ± 0.16 | 3.28 ± 0.38 | 0.013 |
TNF-α plasma level (pg/mL) | 10.70 ± 0.72 | 9.76 ± 1.54 | 9.08 ± 1.49 | 0.006 | 9.98 ± 1.37 | 9.08 ± 1.49 | 0.0015 |
Factor (mean ± SD) | CC | CT | TT |
p
| CT and CC | TT |
p
|
---|---|---|---|---|---|---|---|
TNF-α −1031T/C | |||||||
Weight (kg) (I) all patients | 54.65 ± 11.51 | 62.43 ± 11.29 | 66.22 ± 11.65 | 0.043 | 60.72 ± 11.32 | 66.22 ± 11.65 | 0.042 |
Weight (kg) (I) men | 62.0 ± 10.0 | 63.76 ± 11.29 | 67.87 ± 11.65 | 0.238 | 63.65 ± 11.21 | 67.87 ± 11.65 | 0.198 |
Weight (kg) (I) women | 49 ± 11.51 | 62.67 ± 10.69 | 75 ± 11.28 | 0.043 | 58.11 ± 11.03 | 75 ± 11.28 | 0.049 |
Weight (kg) (VII) all patients | 55.67 ± 9.96 | 59.16 ± 9.54 | 60.54 ± 9.51 | 0.624 | 57.56 ± 9.54 | 60.54 ± 9.51 | 0.424 |
Weight (kg) (VII) men | 60 ± 10 | 58.35 ± 11.29 | 61.20 ± 11.60 | 0.514 | 58.95 ± 9.54 | 61.20 ± 11.60 | 0.409 |
Weight (kg) (VII) women | 47.67 ± 9.97 | 65.0 ± 9.35 | 57.17 ± 9.81 | 0.148 | 54.6 ± 9.42 | 57.17 ± 9.81 | 0.694 |
BMI (I) all patients | 19.58 ± 4.42 | 23.28 ± 4.28 | 23.52 ± 4.45 | 0.125 | 22.40 ± 4.28 | 23.52 ± 4.45 | 0.336 |
BMI (I) men | 22.28 ± 4.31 | 22.76 ± 4.28 | 24.08 ± 4.47 | 0.492 | 22.69 ± 4.28 | 24.08 ± 4.47 | 0.237 |
BMI (I) women | 16.88 ± 4.42 | 22.85 ± 4.07 | 25.43 ± 4.33 | 0.043 | 19.28 ± 4.37 | 25.43 ± 4.33 | 0.250 |
BMI (VII) all patients | 20.22 ± 3.96 | 20.66 ± 3.91 | 20.05 ± 3.91 | 0.851 | 20.55 ± 3.91 | 20.05 ± 3.91 | 0.609 |
BMI (VII) men | 23.03 ± 4.31 | 20.79 ± 3.91 | 21.20 ± 3.91 | 0.369 | 21.29 ± 3.91 | 21.20 ± 3.91 | 0.920 |
BMI (VII) women | 16.41 ± 3.96 | 19.84 ± 3.87 | 20.12 ± 3.96 | 0.134 | 17.78 ± 3.98 | 20.12 ± 3.96 | 0.100 |
Transferrin (g/L) | 2.78 ± 0.40 | 2.58 ± 0.60 | 2.45 ± 0.59 | 0.255 | 2.58 ± 0.60 | 2.45 ± 0.59 | 0.400 |
Prealbumin (g/dL) | 0.283 ± 0.09 | 0.253 ± 0.08 | 0.231 ± 0.08 | 0.262 | 0.261 ± 0.08 | 0.231 ± 0.08 | 0.945 |
TP (g/L) (I) | 6.67 ± 0.51 | 6.68 ± 0.50 | 6.70 ± 0.52 | 0.985 | 6.68 ± 0.50 | 6.70 ± 0.52 | 0.866 |
TP (g/L) (VII) | 5.69 ± 0.72 | 6.40 ± 0.66 | 6.53 ± 0.65 | 0.002 | 6.18 ± 0.66 | 6.53 ± 0.65 | 0.150 |
Albumin (g/L) (I) | 3.19 ± 0.22 | 3.32 ± 0.24 | 3.46 ± 0.24 | 0.014 | 3.29 ± 0.24 | 3.46 ± 0.24 | 0.008 |
Albumin (g/L) (VII) | 2.87 ± 0.43 | 3.09 ± 0.39 | 3.25 ± 0.40 | 0.044 | 3.06 ± 0.39 | 3.25 ± 0.40 | 0.040 |
TNF-α plasma level (pg/mL) | 10.83 ± 1.34 | 9.67 ± 1.60 | 9.31 ± 1.57 | 0.002 | 10.71 ± 1.60 | 9.31 ± 1.57 | < 0.001 |
Factor | CC | CT or TT | p, OR [95% CI] | TT | CT or CC | p, OR [95%CI] | CT | CC or TT | p, OR [95% CI] |
---|---|---|---|---|---|---|---|---|---|
SGA All patients | |||||||||
A | 0 | 9 | 0.527 0.385 [0.020–7.420] | 9 | 0 | 0.055 17.0 [0.941–306.99] | 0 | 9 | 0.108 0.093 [0.005–1.688] |
B and C | 6 (11.3%) | 47 (88.7%) | 28 (52.8%) | 25 (47.2%) | 19 (35.8%) | 34 (64.2%) | |||
A and B | 1 (2.6%) | 37 (97.4%) | 0.044 9.737 [1.061–89.40] | 31 (81.6%) | 7 (18.4%) | 0.0001 13.29 [3.862–45.70] | 6 (15.8%) | 32 (84.2%) | 0.0023 0.159 [0.048–0.519] |
C | 5 (20.8%) | 19 (79.2%) | 6 (25%) | 18 (75%) | 13 (54.2%) | 11 (45.8%) | |||
SGA Without parenteral nutrition | |||||||||
A | 0 | 8 | 0.963 0.929 [0.041–21.16] | 8 | 0 | 0.094 12.14 [0.657–224.57] | 0 | 8 | 0.123 0.101 [0.005–1.865] |
B and C | 2 (4.9%) | 39 (95.1%) | 24 (58.5%) | 17 (41.5%) | 15 (36.6%) | 26 (63.4%) | |||
A and B | 1 (2.9%) | 33 (97.1%) | 0.554 0.424 [0.025–7.272] | 27 (79.4%) | 7 (20.6%) | 0.003 7.714 [1.984–29.99] | 6 (17.6%) | 28 (82.4%) | 0.005 0.143 [0.037–0.556] |
C | 1 (6.7%) | 14 (93.3%) | 5 (33.3%) | 10 (66.7%) | 9 (60%) | 6 (40%) | |||
SGA Parenterally nourished | |||||||||
A | 0 | 1 | 0.790 0.630 [0.021–18.84] | 1 | 0 | 0.317 5.667 [0.189–169.54] | 0 | 1 | 0.790 0.630 [0.021–18.84] |
B and C | 4 (33.3%) | 8 (66.7%) | 4 (33.3%) | 8 (66.7%) | 4 (33.3%) | 8 (66.7%) | |||
A and B | 0 | 4 | 0.218 0.136 [0.006–3.254] | 4 | 0 | 0.023 51.0 [1.705–1525.9] | 0 | 4 | 0.218 0.136 [0.006–3.254] |
C | 4 (44.4%) | 5 (55.6%) | 1 (11.1%) | 8 (88.9%) | 4 (44.4%) | 5 (55.6%) | |||
NRS All patients | |||||||||
2 and 3 | 6 (10%) | 54 (90%) | 0.747 0.596 [0.026–13.83] | 37 (61.7%) | 23 (38.3%) | 0.186 7.979 [0.367–173.59] | 17 (28.3%) | 43 (71.7%) | 0.110 0.080 [0.04–1.762] |
4 | 0 | 2 | 0 | 2 | 2 | 0 | |||
2 | 0 | 42 | 0.015 38.10 [2.019–719.04] | 31 (73.8%) | 11 (26.2%) | 0.002 6.576 [2.025–21.36] | 11 (26.2%) | 31 (73.8%) | 0.273 0.532 [0.172–1.645] |
3 and 4 | 6 (30%) | 14 (70%) | 6 (30%) | 14 (70%) | 8 (40%) | 12 (60%) | |||
NRS Without parenteral nutrition | |||||||||
2 and 3 | 2 (4.2%) | 46 (95.8%) | 0.299 0.161 [0.005–5.052] | 32 (66.7%) | 16 (33.3%) | 0.285 5.909 [0.228–153.17] | 14 (29.2%) | 34 (70.8%) | 0.237 0.140 [0.005–3.646] |
4 | 0 | 1 | 0 | 1 | 1 | 0 | |||
2 | 0 | 34 | 0.107 0.078 [0.004–1.739] | 26 (76.5%) | 8 (23.5%) | 0.017 4.875 [1.326–17.92] | 8 (23.5%) | 26 (76.5%) | 0.112 0.352 [0.097–1.274] |
3 and 4 | 2 (13.3%) | 13 (86.7%) | 6 (40%) | 9 (60%) | 7 (46.7%) | 8 (53.3%) | |||
NRS Parenterally nourished | |||||||||
2 and 3 | 4 (33.3%) | 8 (66.7%) | 0.790 1.588 [0.053–47.52] | 5 (41.7%) | 7 (58.3%) | 0.648 2.200 [0.075–64.91] | 3 (25%) | 9 (75%) | 0.230 0.123 [0.004–3.782] |
4 | 0 | 1 | 0 | 1 | 1 | 0 | |||
2 | 0 | 8 | 0.023 0.020 [0.0-0.587] | 5 (62.5%) | 3 (37.5%) | 0.08 17.29 [0.712–419.95] | 3 (37.5%) | 5 (62.5%) | 0.512 2.40 [0.175–32.88] |
3 and 4 | 4 (80%) | 1 (20%) | 0 | 5 | 1 (20%) | 4 (80%) | |||
BMI (I) All patients | |||||||||
< 24.9 (N and UW) | 5 (12.2%) | 36 (87.8%) | 0.366 2.778 [0.303–25.46] | 22 (53.7%) | 19 (46.3%) | 0.181 0.463 [0.150–1.431] | 14 (34.1%) | 27 (65.9%) | 0.406 1.659 [0.503–5.475] |
> 25.0 (OW) | 1 (4.8%) | 20 (95.2%) | 15 (71.4%) | 6 (28.6%) | 5 (23.8%) | 16 (76.2%) | |||
< 18.5 (UW) | 3 (30%) | 7 (70%) | 0.033 7.0 [1.174–41.74] | 4 (40%) | 6 (60%) | 0.176 0.384 [0.096–1.534] | 3 (30%) | 7 (70%) | 0.962 0.964 [0.221–4.216] |
> 18.5 (N and OW) | 3 (5.8%) | 49 (94.2%) | 33 (63.5%) | 19 (36.5%) | 16 (30.8%) | 36 (69.2%) | |||
BMI (I) Without parenteral nutrition | |||||||||
< 24.9 (N and UW) | 1 (3.1%) | 31 (96.9%) | 0.648 0.516 [0.030–8.805] | 19 (59.4%) | 13 (40.6%) | 0.237 0.450 [0.120–1.691] | 12 (37.5%) | 20 (62.5%) | 0.160 2.80 [0.665–11.79] |
> 25.0 (OW) | 1 (5.9%) | 16 (94.1%) | 13 (76.5%) | 4 (23.5%) | 3 (17.6%) | 14 (82.4%) | |||
< 18.5 (UW) | 0 | 7 | 0.962 2.80 [0.665–11.79] | 4 (57.1%) | 3 (42.9%) | 0.626 0.667 [0.131–3.398] | 3 (42.9%) | 4 (57.1%) | 0.453 1.875 [0.364–9.665] |
> 18.5 (N and OW) | 2 (4.8%) | 40 (95.2%) | 28 (66.7%) | 14 (33.3%) | 12 (28.6%) | 30 (71.4%) | |||
BMI (I) Parenterally nourished | |||||||||
< 24.9 (N and UW) | 4 (44.4%) | 5 (55.6%) | 0.218 7.364 [0.307–176.42] | 3 (33.3%) | 6 (66.7%) | 0.571 0.50 [0.045–5.514] | 2 (22.2%) | 7 (77.8%) | 0.328 0.286 [0.023–3.524] |
> 25.0 (OW) | 0 | 4 | 2 (50%) | 2 (50%) | 2 (50%) | 2 (50%) | |||
< 18.5 (UW) | 3 | 0 | 0.030 44.33 [1.440-1365.15] | 0 | 3 | 0.232 0.143 [0.006–3.471] | 0 | 3 | 0.333 0.206 [0.008–5.051] |
> 18.5 (N and OW) | 1 (10%) | 9 (90%) | 5 (50%) | 5 (50%) | 4 (40%) | 6 (60%) | |||
BMI (VII) All patients | |||||||||
< 24.9 (N and UW) | 6 (12.5%) | 42 (87.5%) | 0.320 4.435 [0.235–83.70] | 28 (58.3%) | 20 (41.7%) | 0.690 0.778 [0.226–2.673] | 14 (29.2%) | 34 (70.8%) | 0.641 0.741 [0.211–2.608] |
> 25.0 (OW) | 0 | 14 | 9 (64.3%) | 5 (35.7%) | 5 (35.7%) | 9 (64.3%) | |||
< 18.5 (UW) | 5 (33.3%) | 10 (66.7%) | 0.006 23.0 [2.416–218.95] | 8 (53.3%) | 7 (46.7%) | 0.566 0.709 [0.220–2.291] | 2 (13.3%) | 13 (86.7%) | 0.111 0.272 [0.055–1.349] |
> 18.5 (N and OW) | 1 (2.1%) | 46 (97.9%) | 29 (61.7%) | 18 (38.3%) | 17 (36.2%) | 30 (63.8%) | |||
BMI (VII) Without parenteral nutrition | |||||||||
< 24.9 (N and UW) | 2 (5.1%) | 37 (94.9%) | 0.832 1.40 [0.062–31.47] | 26 (66.7%) | 13 (33.3%) | 0.693 1.333 [0.319–5.570] | 11 (28.2%) | 28 (71.8%) | 0.473 0.589 [0.139–2.499] |
> 25.0 (OW) | 0 | 10 | 6 (60%) | 4 (40%) | 4 (40%) | 6 (60%) | |||
< 18.5 (UW) | 2 (16.7%) | 10 (83.3%) | 0.07 17.86 [0.794–401.41] | 8 (66.7%) | 4 (33.3%) | 0.909 1.083 [0.273–4.293] | 2 (16.7%) | 10 (83.3%) | 0.240 0.370 [0.070–1.945] |
> 18.5 (N and OW) | 0 | 37 | 24 (64.9%) | 13 (35.1%) | 13 (35.1%) | 24 (64.9%) | |||
BMI VII Parenterally nourished | |||||||||
< 24.9 (N and UW) | 4 (44.4%) | 5 (55.6%) | 0.218 7.364 [0.307–176.42] | 2 (22.2%) | 7 (77.8%) | 0.094 0.095 [0.006–1.498] | 3 (33.3%) | 6 (66.7%) | 0.765 1.50 [0.106–21.31] |
> 25.0 (OW) | 0 | 4 | 3 (75%) | 1 (25%) | 1 (35%) | 3 (75%) | |||
< 18.5 (UW) | 3 | 0 | 0.030 44.33 [1.440-1365.15] | 0 | 3 | 0.232 0.143 [0.005–3.471] | 0 | 3 | 0.333 0.206 [0.008–5.051] |
> 18.5 (N and OW) | 1 (10%) | 9 (90%) | 5 (50%) | 5 (50%) | 4 (40%) | 6 (60%) | |||
Weight loss (I vs VII) All patients | |||||||||
< 5% | 4 (13.3%) | 26 (86.7%) | 0.356 2.308 [0.390–13.64] | 18 (60%) | 12 (40%) | 0.960 1.026 [0.372–2.833] | 8 (26.7%) | 22 (73.3%) | 0.511 0.694 [0.234–2.064] |
> 5% | 2 (6.2%) | 30 (93.8%) | 19 (59.4%) | 13 (40.6%) | 11 (34.4%) | 21 (65.6%) | |||
< 10% | 5 (12.5%) | 35 (87.5%) | 0.331 3.00 [0.328–27.46] | 22 (55%) | 18 (45%) | 0.314 0.570 [0.191-1.70] | 13 (32.5%) | 27 (67.5%) | 0.670 1.284 [0.407–4.047] |
> 10% | 1 (4.5%) | 21 (95.5%) | 15 (68.2%) | 7 (31.8%) | 6 (27.3%) | 16 (72.7%) | |||
Weight loss (I vs VII) Without parenteral nutrition | |||||||||
< 5% | 2 (9.1%) | 20 (90.9%) | 0.227 6.707 [0.305–147.38] | 14 (63.6%) | 8 (36.5%) | 0.825 0.875 [0.269–2.851] | 6 (27.3%) | 16 (72.7%) | 0.648 0.750 [0.219–2.574] |
> 5% | 0 | 27 | 18 (66.7%) | 9 (33.3%) | 9 (33.3%) | 18 (66.7%) | |||
< 10% | 2 (6.5%) | 29 (93.5%) | 0.469 3.136 [0.143–69.02] | 18 (58.1%) | 13 (41.9%) | 0.169 0.396 [0.106–1.482] | 11 (35.5%) | 20 (64.5%) | 0.336 1.925 [0.508–7.298] |
> 10% | 0 | 18 | 14 (77.8%) | 4 (22.2%) | 4 (22.2%) | 14 (77.8%) | |||
Weight loss (I vs VII) Parenterally nourished | |||||||||
< 5% | 2 (25%) | 6 (75%) | 0.571 0.50 [0.045–5.514] | 4 (50%) | 4 (50%) | 0.295 4.00 [0.299–53.47] | 2 (25%) | 6 (75%) | 0.571 0.50 [0.045–5.514] |
> 5% | 2 (40%) | 3 (60%) | 1 (20%) | 4 (80%) | 2 (40%) | 3 (60%) | |||
< 10% | 3 (33.3%) | 6 (66.7%) | 0.765 1.50 [0.106–21.31] | 4 (44.4%) | 5 (55.6%) | 0.512 2.40 [0.175–32.88] | 2 (22.2%) | 7 (77.8%) | 0.328 0.286 [0.023–3.524] |
> 10% | 1 (25%) | 3 (75%) | 1 (25%) | 3 (75%) | 2 (50%) | 2 (50%) |
Factor | Log-rank test | |
---|---|---|
HR [95% CI] |
p
| |
Gender | 1.171 [0.368–3.723] | 0.777 |
Age | 1.132 [0.452–2.837] | 0.792 |
Smoking history | 1.715 [0.515–5.712] | 0.460 |
Alcohol consumption | 1.301 [0.531–3.226] | 0.550 |
Performance status | 3.361 [0.60-18.831] | 0.019 |
Tumor stage | 1.881 [0.676–5.239] | 0.303 |
Parenteral nutrition | 1.617 [0.548–4.772] | 0.322 |
SGA | 2.818 [0.996–7.972] | 0.126 |
NRS | 1.890 [0.644–5.543] | 0.271 |
BMI loss > 5% (I vs VII) | 1.752 [0.695–4.415] | 0.270 |
BMI loss > 10% (I vs VII) | 1.436 [0.578–3.520] | 0.443 |
Weight loss > 5% (I vs VII) | 1.217 [0.489–3.032] | 0.673 |
Weight loss > 10% (I vs VII) | 1.374 [0.556–3.396] | 0.492 |
Total protein (I) | 1.227 [0.499–3.020] | 0.653 |
Albumin (I) | 1.726 [0.698–4.267] | 0.228 |
TNF-α −1031T/C | 4.960 [0.808–30.48] | 0.019 |
Plasma TNF-α | 2.582 [1.031–6.468] | 0.028 |
Cox proportional-hazard regression model | ||
Performance status | 3.10 [0.930–10.31] | 0.047 |
TNF-α −1031T/C | 2.142 [1.124–4.08] | 0.021 |
Overall model fit p = 0.011, stepwise method |